FDA approved the first 4-strain influenza vaccine live, intranasal (FluMist Quadrivalent, MedImmune) for the prevention of influenza. The vaccine?s 4 strains (2 type-A and 2 type-B lineages) help provide broad protection against circulating influenza A and B.
FDA approved the first 4-strain influenza vaccine live, intranasal (FluMist Quadrivalent, MedImmune) for the prevention of influenza.
According MedImmune, all other licensed seasonal influenza vaccines are trivalent, containing 3 strains (2 strains of type-A influenza [A/H1N1 and A/H3N2] and 1 B strain). FluMist Quadrivalent contains 4 strains (2 type-A and 2 type-B lineages) to help provide broad protection against circulating influenza A and B.
The ability to add another strain of influenza B without compromising the vaccine’s ability to protect against the other 3 strains will allow scientists to make a better vaccine, according to Robert Belshe, MD, director of Saint Louis University’s (SLU) Center for Vaccine Development and professor of infectious diseases. SLU conducted the research on the quadrivalent vaccine.
“The intent with the trivalent is to take care of all flu,” Dr Belshe said. “But in reality we have to guess right and put the right strains in the vaccine. We weren’t very good at guessing which strain of B to use. The A and B strains still change, so we have to keep up with that change. Adding the second B strain will certainly help on the B side and be more likely to protect.”
The nasal spray vaccine was tested in approximately 2,300 children between ages 2 and 19 years. The children were randomly assigned to receive 1 of 3 vaccines: a vaccine containing 4 strains of influenza-2 of influenza A and 2 of influenza B, or 1 of 2 vaccines that contained both influenza A strains and 1 of each of the influenza B strains. Researchers looked at the safety and antibody response to both influenza A and B viruses in the children of different age groups who were vaccinated. The children who received vaccine containing 4 strains of flu had as robust of an immune response as those who received the vaccine that contained 3 strains.
The vaccine could be ready for use during the 2013-2014 influenza season, pending a recommendation from the Advisory Committee on Immunization Practices, a group that advises the Centers for Disease Control and Prevention about vaccination issues.
“I expect in the not-too-distant future we’ll see approval of flu shots with 4 strains,” Dr Belshe said.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.